IRCT20161207031288N4已完成2 期
Safety and efficacy assessment of Brimonidine topical formulation on rosacea disease
Jarfandishan-e Navid-e Salamat (Janus) knowledge-based Company0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Having rosacea disease
- •No treatment received in last three months
排除标准
- •More than 5 inflammatory acne lesions
- •Special forms of rosacea in addition to Dermatosis
- •Acute Lupus erythematosus
- •Previous treatment with Brimonidine gel 33%
- •Seborrheic dermatits
研究者
相似试验
Unknown
2 期
Effectiveness and safety OF Brimonidine tartrate in treatment of glaucomaCTRI/2015/12/006473Sun Pharma Advanced Research Company Limited50
已完成
不适用
Efficacy, tolerability and safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischaemic optic neuropathyEye Diseases: Non-arteritic anterior ischemic optic neuropathyEye DiseasesOther disorders of optic [2nd] nerve and visual pathwaysISRCTN72549635Department of Health (UK)
进行中（未招募）
1 期
Patient feedback of persistent facial rednessErythema of rosaceaMedDRA version: 20.0 Level: PT Classification code 10039218 Term: Rosacea System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005686-12-GBGalderma R&D80
进行中（未招募）
1 期
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)Geographic Atrophy Secondary to Age-related Macular DegenerationMedDRA version: 17.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2013-003320-36-ITAllergan Limited320
进行中（未招募）
1 期
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)Geographic Atrophy Secondary to Age-related Macular DegenerationMedDRA version: 20.0 Level: PT Classification code 10025409 Term: Macular degeneration System Organ Class: 10015919 - Eye disordersEUCTR2013-003320-36-DEAllergan Limited310